Fluorescence in situ hybridization analysis is a helpful test for the diagnosis of dermatofibrosarcoma protuberans

Modern Pathology

Volumn 28, Issue 2, 2015, Pages 230-237

  Karanian, Marie ^a,b,c   Pérot, Gaëlle ^a,b   Coindre, Jean Michel ^a,b,c   Chibon, Frédéric ^a,b   Pedeutour, Florence ^d   Neuville, Agnès ^a,b,c  

^a INSTITUT BERGONIÉ   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIGEN; COLIA1-PDGFB FUSION PROTEIN, HUMAN; ONCOPROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; CHILD; CHROMOSOME REARRANGEMENT; COL1A1 PDGFB FUSION GENE; CYTOGENETICS; DERMATOFIBROSARCOMA PROTUBERANS; DIAGNOSTIC TEST; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOLOGIST; PRIORITY JOURNAL; REVIEW; CLINICAL TRIAL; DERMATOFIBROSARCOMA; GENETICS; INFANT; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; SKIN NEOPLASMS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DERMATOFIBROSARCOMA; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84922066765     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.97     Document Type: Review

References (31)

1. Mentzel T, Pedeutour F, Lazar AJF, et al. Dermatofibrosarcoma protuberans. In: Fletcher CDM, Bridge JA, Hogendoorn PCW (eds). World Health Organisation Classification of Tumours of Soft Tissue and Bone. IARC Press: Lyon, France; 2013, pp 77-79.
2. Liu LS, Colegio OR. Molecularly targeted therapies for nonmelanoma skin cancers. Int J Dermatol 2013;52: 654-665.
3. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-3591.
4. Weiss S, Goldblum JR. Dermatofibrosarcoma protuberans, In: Weiss SW, Goldblum JR (eds). Enzinger and Weiss's Soft Tissue Tumors. Mosby: St Louis, MO, USA; 2008, pp 371-382.
5. Pedeutour F, Simon MP, Minoletti F, et al. Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res 1995;55:2400-2403.
6. Pedeutour F, Simon MP, Minoletti F, et al. Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. Cytogenet Cell Genet 1996;72:171-174.
7. Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997;15:95-98.
8. Segura S, Salgado R, Toll A, et al. Identification of t(17;22)(q22;q13) (COL1A1/PDGFB) in dermatofibrosarcoma protuberans by fluorescence in situ hybridization in paraffin-embedded tissue microarrays. Hum Pathol 2011;42:176-184.
9. Ha SY, Lee SE, Kwon MJ, et al. PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications. Hum Pathol 2013;44:1300-1309.
10. Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008;39:184-193.
11. Takahira T, Oda Y, Tamiya S, et al. Detection of COL1A1-PDGFB fusion transcripts and PDGFB/ PDGFRB mRNA expression in dermatofibrosarcoma protuberans. Mod Pathol 2007;20:668-675.
12. Llombart B, Monteagudo C, Sanmartín O, et al. Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors. J Am Acad Dermatol 2011;65:564-575.
13. Minoletti F, Miozzo M, Pedeutour F, et al. Involvement of chromosomes 17 and 22 in dermatofibrosarcoma protuberans. Genes Chromosomes Cancer 1995;13:62-65.
14. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003;37:1-19.
15. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology 2006;48:13-21.
16. Cheah AL, Billings SD. The role of molecular testing in the diagnosis of cutaneous soft tissue tumors. Semin Cutan Med Surg 2012;31:221-233.
17. Neuville A, Ranchère-Vince D, Dei Tos AP, et al. Impact of molecular analysis on the final sarcoma diagnosis: a study on 763 cases collected during a European epidemiological study. Am J Surg Pathol 2013;37:1259-1268.
18. Bianchini L, Maire G, Guillot B, et al. Complex t(5;8) involving the CSPG2 and PTK2B genes in a case of dermatofibrosarcoma protuberans without the COL1A1-PDGFB fusion. Virchows Arch 2008;452: 689-696.
19. Mandahl N, Limon J, Mertens F, et al. Ring marker containing 17q and chromosome 22 in a case of dermatofibrosarcoma protuberans. Cancer Genet Cytogenet. 1996;89:88-91.
20. Naeem R, Lux ML, Huang SF, et al. Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol 1995;147:1553-1558.
21. Dobin SM, Diaz JA, Silva MT, et al. Translocation (17;22)(q22;q13) in a case of subcutaneous dermatofibrosarcoma protuberans in an adult. Cancer Genet Cytogenet 1999;109:86-87.
22. Kutzner H, Mentzel T, Palmedo G, et al. Plaque-like CD34-positive dermal fibroma ("medallion-like dermal dendrocyte hamartoma"): clinicopathologic, immunohistochemical, and molecular analysis of 5 cases emphasizing its distinction from superficial, plaquelike dermatofibrosarcoma protuberans. Am J Surg Pathol 2010;34:190-201.
23. Sonobe H, Furihata M, Iwata J, et al. Dermatofibrosarcoma protuberans harboring t(9;22)(q32;q12.2). Cancer Genet Cytogenet 1999;110:14-18.
24. Sinovic J, Bridge JA. Translocation (2;17) in recurrent dermatofibrosarcoma protuberans. Cancer Genet Cytogenet 1994;75:156-157.
25. Craver RD, Correa H, Kao Y, et al. Dermatofibrosarcoma protuberans with 46,XY,t(X;7) abnormality in a child. Cancer Genet Cytogenet 1995;80:75-77.
26. Bogucki B, Neuhaus I, Hurst EA. Dermatofibrosarcoma protuberans: a review of the literature. Dermatol Surg 2012;38:537-551.
27. Haycox CL, Odland PB, Olbricht SM, et al. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment. J Am Acad Dermatol 1997;37: 438-444.
28. Kim HJ, Lee JY, Kim SH, et al. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34. Br J Dermatol 2007;157: 319-324.
29. Kérob D, Porcher R, Vérola O, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res 2010;16:3288-3295.
30. Kerob D, Pedeutour F, Leboeuf C, et al. Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol 2008;26: 1757-1759.
31. Ray-Coquard I, Ranchère-Vince D, Thiesse P, et al. Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses. Eur J Cancer 2003;39:2021-2025.